[go: up one dir, main page]

ATE524460T1 - Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten - Google Patents

Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten

Info

Publication number
ATE524460T1
ATE524460T1 AT08781867T AT08781867T ATE524460T1 AT E524460 T1 ATE524460 T1 AT E524460T1 AT 08781867 T AT08781867 T AT 08781867T AT 08781867 T AT08781867 T AT 08781867T AT E524460 T1 ATE524460 T1 AT E524460T1
Authority
AT
Austria
Prior art keywords
gpr119
pyridone
protein
receptor agonists
coupled receptor
Prior art date
Application number
AT08781867T
Other languages
English (en)
Inventor
Dean A Wacker
Karen A Rossi
Ying Wang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE524460T1 publication Critical patent/ATE524460T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
AT08781867T 2007-07-17 2008-07-16 Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten ATE524460T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95016207P 2007-07-17 2007-07-17
PCT/US2008/070101 WO2009012275A1 (en) 2007-07-17 2008-07-16 Pyridone gpr119 g protein-coupled receptor agonists

Publications (1)

Publication Number Publication Date
ATE524460T1 true ATE524460T1 (de) 2011-09-15

Family

ID=39864683

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08781867T ATE524460T1 (de) 2007-07-17 2008-07-16 Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
AT08781868T ATE540945T1 (de) 2007-07-17 2008-07-16 Verfahren zur modulation des gpr119-g- proteingekoppelten rezeptors und ausgewählte verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08781868T ATE540945T1 (de) 2007-07-17 2008-07-16 Verfahren zur modulation des gpr119-g- proteingekoppelten rezeptors und ausgewählte verbindungen

Country Status (27)

Country Link
US (6) US8003796B2 (de)
EP (2) EP2173737B1 (de)
JP (3) JP5301539B2 (de)
KR (2) KR20100045471A (de)
CN (3) CN101801957A (de)
AR (2) AR067568A1 (de)
AT (2) ATE524460T1 (de)
AU (2) AU2008276057B2 (de)
BR (2) BRPI0814428A2 (de)
CA (2) CA2693444A1 (de)
CL (2) CL2008002110A1 (de)
CO (1) CO6160315A2 (de)
CY (2) CY1112151T1 (de)
DK (2) DK2170864T3 (de)
EA (2) EA016595B1 (de)
ES (2) ES2371515T3 (de)
HK (2) HK1136298A1 (de)
HR (2) HRP20110806T1 (de)
IL (1) IL228120A0 (de)
NZ (2) NZ582661A (de)
PE (2) PE20090449A1 (de)
PL (2) PL2173737T3 (de)
PT (2) PT2173737E (de)
SI (2) SI2173737T1 (de)
TW (2) TW200904439A (de)
WO (2) WO2009012275A1 (de)
ZA (2) ZA201000151B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2588867A1 (en) * 2004-12-01 2006-06-08 Banyu Pharmaceutical Co., Ltd. Substituted pyridone derivative
EP2144902B1 (de) 2007-05-04 2012-05-16 Bristol-Myers Squibb Company An gpr119-g-protein gekoppelte [6,6]und [6,7]-bicyclische rezeptoragonisten
ATE524460T1 (de) * 2007-07-17 2011-09-15 Bristol Myers Squibb Co Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
EP2146210A1 (de) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
AU2009270971A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
JP2011528369A (ja) * 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびそれらの使用方法
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
WO2010106457A2 (en) * 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
BR112012000831A2 (pt) 2009-06-24 2019-09-24 Boehringer Ingelheim Int compostos, composições farmacêuticas e métodos relacionados
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2547339A1 (de) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Kombination eines gpr119-agonisten und des dpp-iv-hemmers linagliptin zur verwendung bei der behandlung von diabetes und zugehöriger erkrankungen
SG184168A1 (en) 2010-04-08 2012-10-30 Bristol Myers Squibb Co Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
EP2566860B1 (de) 2010-05-06 2014-09-10 Bristol-Myers Squibb Company Bicyclische heteroaryl verbindungen als gpr119 modulatoren
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8785463B2 (en) 2010-10-08 2014-07-22 Cadila Healthcare Limited GPR 119 agonists
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
EP3469907B1 (de) 2010-12-06 2021-03-03 Aclaris Therapeutics, Inc. Substituierte pyridinon-pyridinyl-verbindungen
US8822471B2 (en) * 2011-03-14 2014-09-02 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
EP2718279B1 (de) 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Neue verbindungen als gpr119 modulatoren
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
AR091739A1 (es) 2012-07-11 2015-02-25 Elcelyx Therapeutics Inc Composiciones y metodos para reducir el riesgo cardiometabolico
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR102160841B1 (ko) * 2012-11-13 2020-09-28 닛산 가가쿠 가부시키가이샤 2-피리돈 화합물
CN102993088A (zh) * 2012-12-31 2013-03-27 东华大学 一种4-羟基-2-吡啶酮的制备方法
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
RS61724B1 (sr) 2013-06-07 2021-05-31 Aclaris Therapeutics Inc Metil/fluoro-piridinil-metoksi supstituisana piridinon-piridinil jedinjenja i fluoro-pirimidinil-metoksi supstituisana piridinon-piridinil jedinjenja
WO2014202505A1 (de) 2013-06-20 2014-12-24 Bayer Cropscience Ag Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
ES2761571T3 (es) 2013-06-20 2020-05-20 Bayer Cropscience Ag Derivados de arilsulfuro y arilsulfóxido como acaricidas e insecticidas
TW201542532A (zh) 2013-07-08 2015-11-16 Bayer Cropscience Ag 作為殺蟲劑的六員ｃ－ｎ－鍵結之芳基硫化物及芳基亞碸衍生物
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
EP2929883A1 (de) 2014-04-08 2015-10-14 Institut Pasteur Pyrazolderivate als Dihydroorotat-Dehydrogenase-(DHODH)-Hemmer
EP3191468B1 (de) 2014-09-11 2018-12-12 Janssen Pharmaceutica NV Substituierte 2-azabicyclen und deren verwendung als orexin rezeptor-modulatoren
WO2016130652A1 (en) 2015-02-10 2016-08-18 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 3
JP6578116B2 (ja) * 2015-03-25 2019-09-18 公益財団法人相模中央化学研究所 一置換（フルオロアルキル）エチレン類及びその製造方法
US10865194B2 (en) 2017-11-03 2020-12-15 Fondazione Istituto Italiano Di Tecnologia Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
JP2023516187A (ja) 2020-02-28 2023-04-18 キャリーオペ，インク． Ｇｐｒ４０アゴニスト
CA3172203A1 (en) 2020-03-27 2021-09-30 Gary A. Decrescenzo Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds
KR20230012597A (ko) 2020-05-19 2023-01-26 칼리오페, 인크. Ampk 활성화제
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
WO2022081573A1 (en) * 2020-10-12 2022-04-21 University Of Tennessee Research Foundation Transient receptor potential canonical 3 inhibitors and methods of use thereof
CN115504927A (zh) * 2022-08-15 2022-12-23 广西中医药大学 4-甲基-2-对甲苯基-6-羰基吡啶-3-甲酸及其制备方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826643A (en) * 1967-08-07 1974-07-30 American Cyanamid Co Method of controlling undesirable plant species using 3-nitropyridines
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) * 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5770615A (en) * 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US6566384B1 (en) * 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
UA57811C2 (uk) 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
BR9911621A (pt) 1998-07-06 2001-10-16 Bristol Myers Squibb Co Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
CA2348740A1 (en) 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
WO2002002519A2 (en) 2000-06-29 2002-01-10 Bristol-Myers Squibb Pharma Company THROMBIN OR FACTOR Xa INHIBITORS
ATE348152T1 (de) 2000-12-01 2007-01-15 Astellas Pharma Inc Verfahren zum screening von diabetes- heilverfahren
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7998986B2 (en) * 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
PT1490064E (pt) * 2002-02-14 2009-12-28 Pharmacia Corp Piridinonas substituídas como moduladores de p38 map-quinase
KR101078098B1 (ko) 2003-01-14 2011-10-28 아레나 파마슈티칼스, 인크. 대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료
MXPA05007614A (es) 2003-02-24 2006-05-25 Arena Pharm Inc Derivados de fenilo y piridilpiperidina como moduladores del metabolismo de glucosa.
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7003597B2 (en) * 2003-07-09 2006-02-21 International Business Machines Corporation Dynamic reallocation of data stored in buffers based on packet size
UA86943C2 (ru) * 2003-07-11 2009-06-10 Арена Фармасьютикалз, Инк. Тризамещенные производные арилов и гетероарилов как модуляторы метаболизма и профилактика и лечение связанных с ними нарушений
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
TWI335328B (en) 2003-07-14 2011-01-01 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
US20070088163A1 (en) 2003-09-12 2007-04-19 Kemia, Inc. Modulators of calcitonin and amylin activity
EP1741703A4 (de) * 2004-03-05 2009-11-25 Banyu Pharma Co Ltd Pyridonderivat
WO2005089786A2 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
KR100893449B1 (ko) * 2004-05-03 2009-04-17 에프. 호프만-라 로슈 아게 간-ｘ-수용체 조절제로서의 인돌일 유도체
MXPA06014129A (es) 2004-06-04 2007-03-07 Arena Pharm Inc Derivados de arilo y heteroarilo sustituidos como moduladores del metabolismo y profilaxis y tratamiento de trastornos relacionados con los mismos.
JP5065908B2 (ja) 2004-12-24 2012-11-07 プロシディオン・リミテッド Ｇタンパク質結合受容体作動薬
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US20060292073A1 (en) * 2005-06-23 2006-12-28 Emory University Stereoselective Synthesis of Amino Acid Analogs for Tumor Imaging
EP1907384A2 (de) 2005-06-30 2008-04-09 Prosidion Limited Gpcr-agonisten
JP5114395B2 (ja) * 2005-06-30 2013-01-09 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
EP2144902B1 (de) * 2007-05-04 2012-05-16 Bristol-Myers Squibb Company An gpr119-g-protein gekoppelte [6,6]und [6,7]-bicyclische rezeptoragonisten
EP2152707B1 (de) * 2007-05-04 2012-06-20 Bristol-Myers Squibb Company An gpr119-g-protein gekoppelte [6,5]-bicyclische rezeptoragonisten
ATE524460T1 (de) * 2007-07-17 2011-09-15 Bristol Myers Squibb Co Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten

Also Published As

Publication number Publication date
IL228120A0 (en) 2013-09-30
AU2008276055A1 (en) 2009-01-22
CN101801956B (zh) 2013-11-20
JP5301539B2 (ja) 2013-09-25
DK2173737T3 (da) 2012-05-07
JP2010533726A (ja) 2010-10-28
PL2173737T3 (pl) 2012-06-29
DK2170864T3 (da) 2012-01-16
AU2008276057B2 (en) 2013-01-31
TW200904439A (en) 2009-02-01
CL2008002110A1 (es) 2008-10-24
AR067568A1 (es) 2009-10-14
US20110245227A1 (en) 2011-10-06
SI2173737T1 (sl) 2012-05-31
AU2008276055B2 (en) 2013-01-31
ATE540945T1 (de) 2012-01-15
NZ582664A (en) 2012-03-30
PE20090888A1 (es) 2009-07-15
KR20100045471A (ko) 2010-05-03
CY1112751T1 (el) 2016-02-10
AR067569A1 (es) 2009-10-14
EA016595B1 (ru) 2012-06-29
EA018709B1 (ru) 2013-10-30
CN103550218A (zh) 2014-02-05
US20110190327A1 (en) 2011-08-04
ZA201000326B (en) 2011-03-30
PL2170864T3 (pl) 2012-02-29
JP5318867B2 (ja) 2013-10-16
US20090042919A1 (en) 2009-02-12
BRPI0815097A2 (pt) 2018-07-24
CN101801957A (zh) 2010-08-11
SI2170864T1 (sl) 2012-04-30
US8178561B2 (en) 2012-05-15
NZ582661A (en) 2012-03-30
EA201000211A1 (ru) 2010-06-30
US8232404B2 (en) 2012-07-31
HRP20120221T1 (hr) 2012-04-30
CO6160315A2 (es) 2010-05-20
PE20090449A1 (es) 2009-04-18
PT2173737E (pt) 2012-03-19
KR20100051814A (ko) 2010-05-18
AU2008276057A1 (en) 2009-01-22
EP2173737A1 (de) 2010-04-14
EP2173737B1 (de) 2012-01-11
EA201000210A1 (ru) 2010-06-30
US8003796B2 (en) 2011-08-23
CL2008002111A1 (es) 2008-10-24
US20120258959A1 (en) 2012-10-11
JP2013237680A (ja) 2013-11-28
CA2693439A1 (en) 2009-01-22
CN101801956A (zh) 2010-08-11
HRP20110806T1 (hr) 2011-11-30
HK1136298A1 (en) 2010-06-25
ES2378914T3 (es) 2012-04-19
WO2009012275A9 (en) 2010-03-11
US7928230B2 (en) 2011-04-19
WO2009012275A1 (en) 2009-01-22
CY1112151T1 (el) 2015-12-09
PT2170864E (pt) 2011-11-25
US20120232048A1 (en) 2012-09-13
EP2170864B1 (de) 2011-09-14
WO2009012277A1 (en) 2009-01-22
HK1143136A1 (en) 2010-12-24
CA2693444A1 (en) 2009-01-22
EP2170864A1 (de) 2010-04-07
US20090023702A1 (en) 2009-01-22
ES2371515T3 (es) 2012-01-04
US8513424B2 (en) 2013-08-20
JP2010533727A (ja) 2010-10-28
BRPI0814428A2 (pt) 2015-01-06
TW200904440A (en) 2009-02-01
ZA201000151B (en) 2011-03-30

Similar Documents

Publication Publication Date Title
ATE524460T1 (de) Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
LTPA2020513I1 (lt) S1P receptoriaus agonisto dozavimas
BRPI0820447A2 (pt) Agonistas do receptor de glicocorticóides
BRPI0806500A2 (pt) Agonistas gpcr de piperidina
EP1981902A4 (de) Nogo-rezeptorantagonisten
ATE531710T1 (de) Piperidin-gpcr-agonisten
EP2244575A4 (de) Angiotensin-ii-rezeptorantagonisten
GB0720390D0 (en) G-Protein coupled receptor agonists
EP2350060A4 (de) Melanocortin-rezeptor-agonisten
GB0720389D0 (en) G-Protein Coupled Receptor Agonists
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
EP2150115A4 (de) Cyclopropylpyrrolidinorexin-rezeptorantagonisten
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
GB0607196D0 (en) G-protein coupled receptor agonists
EP2173174A4 (de) Farnesoid-x-rezeptor-agonisten
EP2079307A4 (de) Farnesoid-x-rezeptor-agonisten
EP2170072A4 (de) Farnesoid-x-rezeptor-agonisten
ATE535521T1 (de) Hydroxymethyl-pyrrolidine als beta-3-adrenerge rezeptoragonisten
DK2081951T3 (da) Progesteron-receptorantagonister
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
EP2349267A4 (de) Pyridazin-carbonsäureamid-orexin-rezeptor-antagonisten
EP2490709A4 (de) Peptidische glp-2-agonisten
EP2151236A4 (de) G-protein-konjugierter rezeptoragonist
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
DK2009992T3 (da) Il-8 receptor-antagonister

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2170864

Country of ref document: EP